Literature DB >> 2802979

Long-term results with primary retroperitoneal tumors.

C W Pinson1, S G ReMine, W S Fletcher, J W Braasch.   

Abstract

Primary retroperitoneal tumors represent a variety of lesions, with different treatments and prognoses. Of 182 patients in our study, retroperitoneal tumor was recognized preoperatively in only 39% of them. Sarcomas were most common (43% of patients), followed by lymphomas (23%), benign tumors (11%), undifferentiated malignant tumors (11%), carcinomas (8%), and germ cell tumors (4%). In 81 patients since 1960, the resection rate was 50%. Operative determinants of resectability were pathologic category and grade and extent of tumor. Resection included segments of the gastrointestinal tract (30% of the patients), kidney (25%), and pancreas, bladder, spleen, aorta, and vena cava (for each, 5% or less of the patients). The operative mortality was 6%. Tumor caused late death in 95% of the patients. Pathologic findings were a significant determinant of survival in the 81 patients. For sarcomas, 69% of the patients underwent resection, and the 1- and 5-year actuarial survival rates were 80% and 43%, respectively. Sixty percent of these patients underwent multiple operations. For lymphomas, most patients were treated with radiotherapy and chemotherapy; the 1- and 5-year survival rates were 67% and 35%, respectively. Benign tumors, almost all resected, yielded a 5-year survival rate of 100%. Undifferentiated tumors and carcinomas, most treated with radiotherapy and chemotherapy, had a 1-year survival rate of less than 33%. Other determinants of survival were age, weight loss, grade of tumor, and extent of tumor. Patients who underwent palliative resection had the same survival rate as patients who underwent biopsy alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2802979     DOI: 10.1001/archsurg.1989.01410100070012

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  30 in total

1.  Schwannoma of the psoas major muscle presenting with abdominal and back pain.

Authors:  Karl J D'Silva; Amit J Dwivedi; John M Barnwell
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  A systemic "dumb-bell" haemangiopericytoma.

Authors:  F Tancioni; P Gaetani; F Tartara; L Villani; A Martelli; R Rodriguez y Baena
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 3.  Primary retroperitoneal liposarcoma: a case report and review of the literature.

Authors:  E Ulusoy; S Beyribey; S Basşay; M Centinkaya
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

4.  Rare presentation of retroperitoneal schwannoma: a case report.

Authors:  Mohammad Mozafar; Saran Lotfollahzadeh; Khashayar Atqiaee; Farideh Adhamy
Journal:  Iran J Cancer Prev       Date:  2014

5.  [Presacral schwannoma with degenerated areas ("ancient schwannoma")].

Authors:  C Netsch; K Oberhagemann; T Bach; B Feyerabend; A J Gross
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

6.  Giant primary retroperitoneal teratoma in an adult: a case report.

Authors:  Poonam Mathur; Miguel A Lopez-Viego; Myron Howell
Journal:  Case Rep Med       Date:  2010-08-24

7.  Curative surgery for locally advanced retroperitoneal mature teratoma in an adult. Case report.

Authors:  Inanc Samil Sarici; Kursat Rahmi Serin; Orhan Agcaoglu; Necip Akman; Adem Ucar; Orhan Bilge
Journal:  Int J Surg Case Rep       Date:  2012-09-28

8.  Retroperitoneal dermoid cyst mimicking a liposarcoma based on imaging assessment: case report and literature review.

Authors:  Xiaomu Ma; Jianchun Xiao; Weibin Wang
Journal:  Gland Surg       Date:  2021-06

9.  Primary Retroperitoneal Teratoma in a Young Male: A Case Report.

Authors:  Charan Singh; Niladri M Raypattanaik; Ishan Sharma; Lileswar Kaman
Journal:  Cureus       Date:  2021-06-01

Review 10.  A giant pelvic malignant schwannoma: a case report and literature review.

Authors:  Hao Xu; Nan Sha; He-Wen Li; Mei Bai; Xin Chen; Hai-Long Hu; Chang-Li Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.